Latest News & Features
Americas
Patents core to the breakthrough gene-editing technology CRISPR belong to the University of Harvard and the Massachusetts Institute of Technology’s Broad Institute, the US Patent and Trademark Office has ruled. 1 March 2022
Big Pharma
Japan-based Ono Pharmaceuticals has sued AstraZeneca, accusing the US pharma company of infringing patents covering an antibody used in cancer treatment. 1 March 2022
Big Pharma
Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation. 1 March 2022
Big Pharma
Allen & Overy has hired five partners from Goodwin Procter to boost its US life sciences litigation practice. 24 February 2022
Africa
The global pandemic has increased collaboration and a new wave of disputes is likely. Arbitration is well placed to help, argue Kate Davies McGill, Gaela Gehring Flores and Paul Keller of Allen & Overy 24 February 2022
Big Pharma
AstraZeneca has sued Taro Pharmaceuticals in two US federal courts alleging that Taro’s planned generic blood-thinning treatment infringes a patent for its Brilinta (ticagrelor) medication. 24 February 2022
Americas
Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents. 24 February 2022
Americas
The Quebec Court of Appeal in Canada has ruled that the 2019 amendments to the Patented Medicines Regulations, governing the country’s Patented Medicine Prices Review Board (PMPRB) are partially invalid. 22 February 2022
Americas
Johnson & Johnson unit Janssen Pharmaceuticals has filed a suit against Intas Pharmaceuticals, seeking to block the India-based drugmaker from launching a generic version of schizophrenia drug Invega Sustenna (paliperidone palmitate). 22 February 2022
Americas
US Senator Elizabeth Warren has urged the Department of Health and Human Services (HHS) to seize control of patents covering Pfizer’s prostate cancer drug Xtandi (enzalutamide). 22 February 2022